Αρχειοθήκη ιστολογίου

Τετάρτη 29 Αυγούστου 2018

Erythema nodosum–like eruption in the setting of sorafenib therapy

Background: Sorafenib, a small molecule inhibitor of RAF kinase and VEGFR-2/PDGFR-beta, is approved for use in several cancers. Numerous cutaneous adverse events from sorafenib therapy have been reported. To the best of our knowledge, we report the first case of erythema nodosum (EN)–like eruption concurrent with sorafenib therapy.

https://ift.tt/2N3ChiU

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου